Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    European Heart Journal Date published:

  • Procedural Volumes in the Era of COVID: The Risk Versus Benefit Trade-Off

    Heart, Lung and Circulation Date published:

  • Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

    Diabetologia Date published:

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published:

  • Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

    Diabetologia Date published:

  • Sex Disparities in Sudden Cardiac Death

    Circulation: Arrhythmia and Electrophysiology Date published:

  • Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction

    Current Heart Failure Reports Date published:

  • Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT

    Journal of Cardiac Failure Date published:

  • Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial

    The American Journal of Clinical Nutrition Date published:

  • Why Are We Forgetting Patients With Peripheral Arterial Disease?

    Heart, Lung and Circulation Date published:

  • Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

    Cardiovascular Research Date published:

  • The long-term cardiovascular impact of hypertension in pregnancy - A missed opportunity

    Australian and New Zealand Journal of Obstetrics and Gynaecology Date published:

  • Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data

    The Lancet Date published:

  • Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

    ESC Heart Failure Date published: